Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
25R0rV3DFD3tvzhr
